Wilmington Funds Management’s AstraZeneca AZN Stock Holding History

Wilmington Funds Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$6.56M	Buy	+88,300	New	+$6.38M	0.66%	34

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MCM

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wilmington Funds Management's AZN Position: Q2 2014 in Review

Wilmington Funds Management opened a new position in AstraZeneca (AZN) in Q2 2014: 88,300 shares worth $6.56M. The stake represents 0.66% of the portfolio and ranks #34 among its holdings.

419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Wilmington Funds Management held 88,300 shares of AstraZeneca worth $6.56M as of Q2 2014.
AstraZeneca was a new Wilmington Funds Management position in Q2 2014.
AstraZeneca made up 0.66% of Wilmington Funds Management's portfolio in Q2 2014, its #34 holding.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.